29 results on '"Gigante, Valeria"'
Search Results
2. Workhorse Antibiotics are in Jeopardy: Resistance Trajectories and the Need for an R&D Response
- Author
-
McDonnell, Anthony, primary, Klemperer, Katherine, additional, Madden, Jacob, additional, Morton, Alec, additional, Khine-Zaw, Yuzana, additional, Colson, Abigail, additional, Amir, Afreenish, additional, Apisarnthanarak, Anucha, additional, El-Sharif, Amany, additional, Gales, Ana Cristina, additional, Gigante, Valeria, additional, Huang, Xun, additional, Iredell, Jonathan, additional, Ohmagari, Norio, additional, Sati, Hatim, additional, Sharland, Mike, additional, Song, Jae-Hoon, additional, Stelling, John, additional, Taneja, Neelam, additional, Essack, Sabiha Yusuf, additional, and Outterson, Kevin, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Candida glabrata (Nakaseomyces glabrata): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal Priority Pathogens List.
- Author
-
Beardsley, Justin, Kim, Hannah Yejin, Dao, Aiken, Kidd, Sarah, Alastruey-Izquierdo, Ana, Sorrell, Tania C, Tacconelli, Evelina, Chakrabarti, Arunaloke, Harrison, Thomas S, Bongomin, Felix, Gigante, Valeria, Galas, Marcelo, Siswanto, Siswanto, Dagne, Daniel Argaw, Roitberg, Felipe, Sati, Hatim, Morrissey, C Orla, and Alffenaar, Jan-Willem
- Abstract
Recognising the growing global burden of fungal infections, the World Health Organization (WHO) established an advisory group consisting of experts in fungal diseases to develop a Fungal Priority Pathogen List. Pathogens were ranked based on their research and development needs and perceived public health importance using a series of global surveys and pathogen characteristics derived from systematic reviews. This systematic review evaluates the features and global impact of invasive disease caused by Candida glabrata (Nakaseomyces glabrata). PubMed and Web of Science were searched for studies reporting on mortality, morbidity (hospitalization and disability), drug resistance (including isolates from sterile and non-sterile sites, since these reflect the same organisms causing invasive infections), preventability, yearly incidence, diagnostics, treatability, and distribution/emergence in the last 10 years. Candida glabrata (N. glabrata) causes difficult-to-treat invasive infections, particularly in patients with underlying conditions such as immunodeficiency, diabetes, or those who have received broad-spectrum antibiotics or chemotherapy. Beyond standard infection prevention and control measures, no specific preventative measures have been described. We found that infection is associated with high mortality rates and that there is a lack of data on complications and sequelae. Resistance to azoles is common and well described in echinocandins—in both cases, the resistance rates are increasing. Candida glabrata remains mostly susceptible to amphotericin and flucytosine. However, the incidence of the disease is increasing, both at the population level and as a proportion of all invasive yeast infections, and the increases appear related to the use of antifungal agents. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Candida albicans—A systematic review to inform the World Health Organization Fungal Priority Pathogens List.
- Author
-
Parambath, Sarika, Dao, Aiken, Kim, Hannah Yejin, Zawahir, Shukry, Izquierdo, Ana-Alastruey, Tacconelli, Evelina, Govender, Nelesh, Oladele, Rita, Colombo, Arnaldo, Sorrell, Tania, Ramon-Pardo, Pilar, Fusire, Terence, Gigante, Valeria, Sati, Hatim, Morrissey, C Orla, Alffenaar, Jan-Willem, and Beardsley, Justin
- Abstract
Candida albicans is a common fungal pathogen and amongst the leading causes of invasive candidiasis globally. This systematic review examines the characteristics and global impact of invasive infections caused by C. albicans. We searched on PubMed and Web of Science for studies reporting on criteria such as mortality, morbidity, drug resistance, preventability, yearly incidence, and distribution/emergence during the period from 2016 to 2021. Our findings indicate that C. albicans is the most common Candida species causing invasive disease and that standard infection control measures are the primary means of prevention. However, we found high rates of mortality associated with infections caused by C. albicans. Furthermore, there is a lack of data on complications and sequelae. Resistance to commonly used antifungals remains rare. Although, whilst generally susceptible to azoles, we found some evidence of increasing resistance, particularly in middle-income settings—notably, data from low-income settings were limited. Candida albicans remains susceptible to echinocandins, amphotericin B, and flucytosine. We observed evidence of a decreasing proportion of infections caused by C. albicans relative to other Candida species, although detailed epidemiological studies are needed to confirm this trend. More robust data on attributable mortality, complications, and sequelae are needed to understand the full extent of the impact of invasive C. albicans infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.
- Author
-
Clark, Julia E, Kim, Hannah Yejin, van de Sande, Wendy W J, McMullan, Brendan, Verweij, Paul, Alastruey-Izquierdo, Ana, Chakrabarti, Arunaloke, Harrison, Thomas S, Bongomin, Felix, Hay, Roderick J, Oladele, Rita, Heim, Jutta, Beyer, Peter, Galas, Marcelo, Siswanto, Siswanto, Dagne, Daniel Argaw, Roitberg, Felipe, Gigante, Valeria, Beardsley, Justin, and Sati, Hatim
- Abstract
The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal priority pathogens list. This systematic review aimed to evaluate the epidemiology and impact of eumycetoma. PubMed and Web of Science were searched to identify studies published between 1 January 2011 and 19 February 2021. Studies reporting on mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence during the study time frames were selected. Overall, 14 studies were eligible for inclusion. Morbidity was frequent with moderate to severe impairment of quality of life in 60.3%, amputation in up to 38.5%, and recurrent or long-term disease in 31.8%–73.5% of patients. Potential risk factors included male gender (56.6%–79.6%), younger age (11–30 years; 64%), and farming occupation (62.1%–69.7%). Mycetoma was predominantly reported in Sudan, particularly in central Sudan (37%–76.6% of cases). An annual incidence of 0.1/100 000 persons and 0.32/100 000 persons/decade was reported in the Philippines and Uganda, respectively. In Uganda, a decline in incidence from 3.37 to 0.32/100 000 persons between two consecutive 10-year periods (2000–2009 and 2010–2019) was detected. A community-based, multi-pronged prevention programme was associated with a reduction in amputation rates from 62.8% to 11.9%. With the pre-specified criteria, no studies of antifungal drug susceptibility, mortality, and hospital lengths of stay were identified. Future research should include larger cohort studies, greater drug susceptibility testing, and global surveillance to develop evidence-based treatment guidelines and to determine more accurately the incidence and trends over time. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Cryptococcosis—a systematic review to inform the World Health Organization Fungal Priority Pathogens List.
- Author
-
Dao, Aiken, Kim, Hannah Yejin, Garnham, Katherine, Kidd, Sarah, Sati, Hatim, Perfect, John, Sorrell, Tania C, Harrison, Thomas, Rickerts, Volker, Gigante, Valeria, Alastruey-Izquierdo, Ana, Alffenaar, Jan-Willem, Morrissey, C Orla, Chen, Sharon C-A, and Beardsley, Justin
- Abstract
Cryptococcosis causes a high burden of disease worldwide. This systematic review summarizes the literature on Cryptococcus neoformans and C. gattii infections to inform the World Health Organization's first Fungal Priority Pathogen List. PubMed and Web of Science were used to identify studies reporting on annual incidence, mortality, morbidity, antifungal resistance, preventability, and distribution/emergence in the past 10 years. Mortality rates due to C. neoformans were 41%–61%. Complications included acute renal impairment, raised intracranial pressure needing shunts, and blindness. There was moderate evidence of reduced susceptibility (MIC range 16–32 mg/l) of C. neoformans to fluconazole, itraconazole, ketoconazole, voriconazole, and amphotericin B. Cryptococcus gattii infections comprised 11%–33% of all cases of invasive cryptococcosis globally. The mortality rates were 10%–23% for central nervous system (CNS) and pulmonary infections, and ∼43% for bloodstream infections. Complications described included neurological sequelae (17%–27% in C. gattii infections) and immune reconstitution inflammatory syndrome. MICs were generally low for amphotericin B (MICs: 0.25–0.5 mg/l), 5-flucytosine (MIC range: 0.5–2 mg/l), itraconazole, posaconazole, and voriconazole (MIC range: 0.06–0.5 mg/l). There is a need for increased surveillance of disease phenotype and outcome, long-term disability, and drug susceptibility to inform robust estimates of disease burden. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Candida auris—a systematic review to inform the world health organization fungal priority pathogens list.
- Author
-
Kim, Hannah Yejin, Nguyen, Thi Anh, Kidd, Sarah, Chambers, Joshua, Alastruey-Izquierdo, Ana, Shin, Jong-Hee, Dao, Aiken, Forastiero, Agustina, Wahyuningsih, Retno, Chakrabarti, Arunoloke, Beyer, Peter, Gigante, Valeria, Beardsley, Justin, Sati, Hatim, Morrissey, C Orla, and Alffenaar, Jan-Willem
- Abstract
The World Health Organization (WHO) in 2022 developed a fungal priority pathogen list. Candida auris was ultimately ranked as a critical priority pathogen. PubMed and Web of Science were used to find studies published from 1 January 2011 to 18 February 2021, reporting on predefined criteria including: mortality, morbidity (i.e. hospitalization and disability), drug resistance, preventability, yearly incidence, and distribution/emergence. Thirty-seven studies were included in the final analysis. The overall and 30-day mortality rates associated with C. auris candidaemia ranged from 29% to 62% and 23% to 67%, respectively. The median length of hospital stay was 46–68 days, ranging up to 140 days. Late-onset complications of C. auris candidaemia included metastatic septic complications. Resistance rates to fluconazole were as high as 87%–100%. Susceptibility to isavuconazole, itraconazole, and posaconazole varied with MIC90 values of 0.06–1.0 mg/l. Resistance rates to voriconazole ranged widely from 28% to 98%. Resistance rates ranged between 8% and 35% for amphotericin B and 0%–8% for echinocandins. Over the last ten years, outbreaks due to C. auris have been reported in in all WHO regions. Given the outbreak potential of C. auris , the emergence and spread of MDR strains, and the challenges associated with its identification, and eradication of its environmental sources in healthcare settings, prevention and control measures based on the identified risk factors should be evaluated for their effectiveness and feasibility. Global surveillance studies could better inform the incidence rates and distribution patterns to evaluate the global burden of C. auris infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Candida tropicalis—A systematic review to inform the World Health Organization of a fungal priority pathogens list.
- Author
-
Keighley, Caitlin, Kim, Hannah Yejin, Kidd, Sarah, Chen, Sharon C-A, Alastruey, Ana, Dao, Aiken, Bongomin, Felix, Chiller, Tom, Wahyuningsih, Retno, Forastiero, Agustina, Al-Nuseirat, Adi, Beyer, Peter, Gigante, Valeria, Beardsley, Justin, Sati, Hatim, Morrissey, C Orla, and Alffenaar, Jan-Willem
- Abstract
In response to the growing global burden of fungal infections with uncertain impact, the World Health Organization (WHO) established an Expert Group to identify priority fungal pathogens and establish the WHO Fungal Priority Pathogens List for future research. This systematic review aimed to evaluate the features and global impact of invasive candidiasis caused by Candida tropicalis. PubMed and Web of Science were searched for studies reporting on criteria of mortality, morbidity (defined as hospitalization and disability), drug resistance, preventability, yearly incidence, diagnostics, treatability, and distribution/emergence from 2011 to 2021. Thirty studies, encompassing 436 patients from 25 countries were included in the analysis. All-cause mortality due to invasive C. tropicalis infections was 55%–60%. Resistance rates to fluconazole, itraconazole, voriconazole and posaconazole up to 40%–80% were observed but C. tropicalis isolates showed low resistance rates to the echinocandins (0%–1%), amphotericin B (0%), and flucytosine (0%–4%). Leukaemia (odds ratio (OR) = 4.77) and chronic lung disease (OR = 2.62) were identified as risk factors for invasive infections. Incidence rates highlight the geographic variability and provide valuable context for understanding the global burden of C. tropicalis infections. C. tropicalis candidiasis is associated with high mortality rates and high rates of resistance to triazoles. To address this emerging threat, concerted efforts are needed to develop novel antifungal agents and therapeutic approaches tailored to C. tropicalis infections. Global surveillance studies could better inform the annual incidence rates, distribution and trends and allow informed evaluation of the global impact of C. tropicalis infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list.
- Author
-
Dao, Aiken, Kim, Hannah Yejin, Halliday, Catriona L, Oladele, Rita, Rickerts, Volker, Govender MMed, Nelesh P, Shin, Jong-Hee, Heim, Jutta, Ford, Nathan Paul, Nahrgang, Saskia Andrea, Gigante, Valeria, Beardsley, Justin, Sati, Hatim, Morrissey, C Orla, Alffenaar, Jan-Willem, and Alastruey-Izquierdo, Ana
- Abstract
Histoplasmosis, a significant mycosis primarily prevalent in Africa, North and South America, with emerging reports globally, poses notable health challenges, particularly in immunocompromised individuals such as people living with HIV/AIDS and organ transplant recipients. This systematic review, aimed at informing the World Health Organization's Fungal Priority Pathogens List, critically examines literature from 2011 to 2021 using PubMed and Web of Science, focusing on the incidence, mortality, morbidity, antifungal resistance, preventability, and distribution of Histoplasma. We also found a high prevalence (22%–44%) in people living with HIV, with mortality rates ranging from 21% to 53%. Despite limited data, the prevalence of histoplasmosis seems stable, with lower estimates in Europe. Complications such as central nervous system disease, pulmonary issues, and lymphoedema due to granuloma or sclerosis are noted, though their burden remains uncertain. Antifungal susceptibility varies, particularly against fluconazole (MIC: ≥32 mg/l) and caspofungin (MICs: 4–32 mg/l), while resistance to amphotericin B (MIC: 0.125–0.16 mg/l), itraconazole (MICs: 0.004–0.125 mg/l), and voriconazole (MICs: 0.004–0.125 mg/l) remains low. This review identifies critical knowledge gaps, underlining the need for robust, globally representative surveillance systems to better understand and combat this fungal threat. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Talaromyces marneffei, Coccidioides species, and Paracoccidioides species—a systematic review to inform the World Health Organization priority list of fungal pathogens.
- Author
-
Morris, Arthur J, Kim, Hannah Yejin, Nield, Blake, Dao, Aiken, McMullan, Brendan, Alastruey-Izquierdo, Ana, Colombo, Arnaldo Lopes, Heim, Jutta, Wahyuningsih, Retno, Le, Thuy, Chiller, Tom M, Forastiero, Agustina, Chakrabarti, Arunaloke, Harrison, Thomas S, Bongomin, Felix, Galas, Marcelo, Siswanto, Siswanto, Dagne, Daniel Argaw, Roitberg, Felipe, and Gigante, Valeria
- Abstract
The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal pathogen priority list. This systematic review aimed to evaluate the epidemiology and impact of infections caused by Talaromyces marneffei, Coccidioides species, and Paracoccidioides species. PubMed and Web of Sciences databases were searched to identify studies published between 1 January 2011 and 23 February 2021 reporting on mortality, complications and sequelae, antifungal susceptibility, preventability, annual incidence, and trends. Overall, 25, 17, and 6 articles were included for T. marneffei, Coccidioides spp. and Paracoccidioides spp. respectively. Mortality rates were high in those with invasive talaromycosis and paracoccidioidomycosis (up to 21% and 22.7%, respectively). Hospitalization was frequent in those with coccidioidomycosis (up to 84%), and while the duration was short (mean/median 3–7 days), readmission was common (38%). Reduced susceptibility to fluconazole and echinocandins was observed for T. marneffei and Coccidioides spp. whereas >88% of T. marneffei isolates had minimum inhibitory concentration values ≤0.015 μg/ml for itraconazole, posaconazole, and voriconazole. Risk factors for mortality in those with talaromycosis included low CD4 counts (odds ratio 2.90 when CD4 count <200 cells/μl compared with 24.26 when CD4 count <50 cells/μl). Outbreaks of coccidioidomycosis and paracoccidioidomycosis were associated with construction work (relative risk 4.4–210.6 and 5.7-times increase, respectively). In the United States of America, cases of coccidioidomycosis increased between 2014 and 2017 (from 8232 to 14 364/year). National and global surveillance as well as more detailed studies to better define sequelae, risk factors, outcomes, global distribution, and trends are required. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Mucorales: A systematic review to inform the World Health Organization priority list of fungal pathogens.
- Author
-
Morrissey, C Orla, Kim, Hannah Yejin, Garnham, Katherine, Dao, Aiken, Chakrabarti, Arunaloke, Perfect, John R, Alastruey-Izquierdo, Ana, Harrison, Thomas S, Bongomin, Felix, Galas, Marcelo, Siswanto, Siswanto, Dagne, Daniel Argaw, Roitberg, Felipe, Gigante, Valeria, Sati, Hatim, Alffenaar, Jan-Willem, and Beardsley, Justin
- Abstract
The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal priority pathogens list (FPPL). This systematic review aimed to evaluate the epidemiology and impact of invasive fungal disease due to Mucorales. PubMed and Web of Science were searched to identify studies published between January 1, 2011 and February 23, 2021. Studies reporting on mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence during the study time frames were selected. Overall, 24 studies were included. Mortality rates of up to 80% were reported. Antifungal susceptibility varied across agents and species, with the minimum inhibitory concentrations lowest for amphotericin B and posaconazole. Diabetes mellitus was a common risk factor, detected in 65%–85% of patients with mucormycosis, particularly in those with rhino-orbital disease (86.9%). Break-through infection was detected in 13.6%–100% on azole or echinocandin antifungal prophylaxis. The reported prevalence rates were variable, with some studies reporting stable rates in the USA of 0.094–0.117/10 000 discharges between 2011 and 2014, whereas others reported an increase in Iran from 16.8% to 24% between 2011 and 2015. Carefully designed global surveillance studies, linking laboratory and clinical data, are required to develop clinical breakpoints to guide antifungal therapy and determine accurate estimates of complications and sequelae, annual incidence, trends, and global distribution. These data will provide robust estimates of disease burden to refine interventions and better inform future FPPL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list.
- Author
-
McMullan, Brendan, Kim, Hannah Yejin, Alastruey-Izquierdo, Ana, Tacconelli, Evelina, Dao, Aiken, Oladele, Rita, Tanti, Daniel, Govender, Nelesh P, Shin, Jong-Hee, Heim, Jutta, Ford, Nathan Paul, Huttner, Benedikt, Galas, Marcelo, Nahrgang, Saskia Andrea, Gigante, Valeria, Sati, Hatim, Alffenaar, Jan Willem, Morrissey, C Orla, and Beardsley, Justin
- Abstract
This systematic review evaluates the current global impact of invasive infections caused by Pneumocystis jirovecii (principally pneumonia: PJP), and was carried out to inform the World Health Organization Fungal Priority Pathogens List. PubMed and Web of Science were used to find studies reporting mortality, inpatient care, complications/sequelae, antifungal susceptibility/resistance, preventability, annual incidence, global distribution, and emergence in the past 10 years, published from January 2011 to February 2021. Reported mortality is highly variable, depending on the patient population: In studies of persons with HIV, mortality was reported at 5%–30%, while in studies of persons without HIV, mortality ranged from 4% to 76%. Risk factors for disease principally include immunosuppression from HIV, but other types of immunosuppression are increasingly recognised, including solid organ and haematopoietic stem cell transplantation, autoimmune and inflammatory disease, and chemotherapy for cancer. Although prophylaxis is available and generally effective, burdensome side effects may lead to discontinuation. After a period of decline associated with improvement in access to HIV treatment, new risk groups of immunosuppressed patients with PJP are increasingly identified, including solid organ transplant patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Pichia kudriavzevii (Candida krusei): A systematic review to inform the World Health Organisation priority list of fungal pathogens.
- Author
-
Nguyen, Thi Anh, Kim, Hannah Yejin, Stocker, Sophie, Kidd, Sarah, Alastruey-Izquierdo, Ana, Dao, Aiken, Harrison, Thomas, Wahyuningsih, Retno, Rickerts, Volker, Perfect, John, Denning, David W, Nucci, Marcio, Cassini, Alessandro, Beardsley, Justin, Gigante, Valeria, Sati, Hatim, Morrissey, C Orla, and Alffenaar, Jan-Willem
- Abstract
In response to the growing global threat of fungal infections, in 2020 the World Health Organisation (WHO) established an Expert Group to identify priority fungi and develop the first WHO fungal priority pathogen list (FPPL). The aim of this systematic review was to evaluate the features and global impact of invasive infections caused by Pichia kudriavzevii (formerly known as Candida krusei). PubMed and Web of Science were used to identify studies published between 1 January 2011 and 18 February 2021 reporting on the criteria of mortality, morbidity (defined as hospitalisation and length of stay), drug resistance, preventability, yearly incidence, and distribution/emergence. Overall, 33 studies were evaluated. Mortality rates of up to 67% in adults were reported. Despite the intrinsic resistance of P. kudriavzevii to fluconazole with decreased susceptibility to amphotericin B, resistance (or non-wild-type rate) to other azoles and echinocandins was low, ranging between 0 and 5%. Risk factors for developing P. kudriavzevii infections included low birth weight, prior use of antibiotics/antifungals, and an underlying diagnosis of gastrointestinal disease or cancer. The incidence of infections caused by P. kudriavzevii is generally low (∼5% of all Candida -like blood isolates) and stable over the 10-year timeframe, although additional surveillance data are needed. Strategies targeting the identified risk factors for developing P. kudriavzevii infections should be developed and tested for effectiveness and feasibility of implementation. Studies presenting data on epidemiology and susceptibility of P. kudriavzevii were scarce, especially in low- and middle-income countries (LMICs). Thus, global surveillance systems are required to monitor the incidence, susceptibility, and morbidity of P. kudriavzevii invasive infections to inform diagnosis and treatment. Timely species-level identification and susceptibility testing should be conducted to reduce the high mortality and limit the spread of P. kudriavzevii in healthcare facilities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list.
- Author
-
Asogan, Mrudhula, Kim, Hannah Yejin, Kidd, Sarah, Alastruey-Izquierdo, Ana, Govender, Nelesh P, Dao, Aiken, Shin, Jong-Hee, Heim, Jutta, Ford, Nathan Paul, Gigante, Valeria, Sati, Hatim, Morrissey, C Orla, Alffenaar, Jan-Willem, and Beardsley, Justin
- Abstract
Candida parapsilosis is globally distributed and recognised for causing an increasing proportion of invasive Candida infections. It is associated with high crude mortality in all age groups. It has been particularly associated with nosocomial outbreaks, particularly in association with the use of invasive medical devices such as central venous catheters. Candida parapsilosis is one of the pathogens considered in the WHO priority pathogens list, and this review was conducted to inform the ranking of the pathogen in the list. In this systematic review, we searched PubMed and Web of Science to find studies between 2011 and 2021 reporting on the following criteria for C. parapsilosis infections: mortality, morbidity (hospitalisation and disability), drug resistance, preventability, yearly incidence, and distribution/emergence. We identified 336 potentially relevant papers, of which 51 were included in the analyses. The included studies confirmed high mortality rates, ranging from 17.5% to 46.8%. Data on disability and sequelae were sparse. Many reports highlighted concerns with azole resistance, with resistance rates of >10% described in some regions. Annual incidence rates were relatively poorly described, although there was clear evidence that the proportion of candidaemia cases caused by C. parapsilosis increased over time. While this review summarises current data on C.parapsilosis , there remains an urgent need for ongoing research and surveillance to fully understand and manage this increasingly important pathogen. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Aspergillus fumigatus—a systematic review to inform the World Health Organization priority list of fungal pathogens.
- Author
-
Morrissey, C Orla, Kim, Hannah Y, Duong, Tra-My N, Moran, Eric, Alastruey-Izquierdo, Ana, Denning, David W, Perfect, John R, Nucci, Marcio, Chakrabarti, Arunaloke, Rickerts, Volker, Chiller, Tom M, Wahyuningsih, Retno, Hamers, Raph L, Cassini, Alessandro, Gigante, Valeria, Sati, Hatim, Alffenaar, Jan-Willem, and Beardsley, Justin
- Abstract
Recognizing the growing global burden of fungal infections, the World Health Organization established a process to develop a priority list of fungal pathogens (FPPL). In this systematic review, we aimed to evaluate the epidemiology and impact of invasive infections caused by Aspergillus fumigatus to inform the first FPPL. The pre-specified criteria of mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence were used to search for relevant articles between 1 January 2016 and 10 June 2021. Overall, 49 studies were eligible for inclusion. Azole antifungal susceptibility varied according to geographical regions. Voriconazole susceptibility rates of 22.2% were reported from the Netherlands, whereas in Brazil, Korea, India, China, and the UK, voriconazole susceptibility rates were 76%, 94.7%, 96.9%, 98.6%, and 99.7%, respectively. Cross-resistance was common with 85%, 92.8%, and 100% of voriconazole-resistant A. fumigatus isolates also resistant to itraconazole, posaconazole, and isavuconazole, respectively. The incidence of invasive aspergillosis (IA) in patients with acute leukemia was estimated at 5.84/100 patients. Six-week mortality rates in IA cases ranged from 31% to 36%. Azole resistance and hematological malignancy were poor prognostic factors. Twelve-week mortality rates were significantly higher in voriconazole-resistant than in voriconazole-susceptible IA cases (12/22 [54.5%] vs. 27/88 [30.7%]; P = .035), and hematology patients with IA had significantly higher mortality rates compared with solid-malignancy cases who had IA (65/217 [30%] vs. 14/78 [18%]; P = .04). Carefully designed surveillance studies linking laboratory and clinical data are required to better inform future FPPL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. WHO Biowaiver Study Project for COVID-19 Outbreak: Dexamethasone Solubility Results for Biopharmaceutical Classification System
- Author
-
Gigante, Valeria, Kopp, Sabine, Sanz, Maria Del Val Bermejo, Pauletti, Giovanni M., and Xu, Minghze
- Subjects
Central nervous system depressants -- Analysis -- Reports -- Health aspects ,COVID-19 -- Analysis -- Health aspects -- Reports ,Dexamethasone -- Reports -- Analysis -- Health aspects ,Health ,World Health Organization -- Reports - Abstract
Dexamethasone is a corticosteroid considered today as one of the few medicines able to reduce mortality in patients infected with COVID-19 who are critically or severely ill (mortality reduction of [...]
- Published
- 2020
17. Scaling Dose-Exposure-Response from Adults to Children
- Author
-
Rusten, Ine Skottheim, Nordmark, Anna, Cole, Susan, Standing, Joseph F., Hietala, Sofia Friberg, Zhao, Wei, Gigante, Valeria, Hamberg, Anna Karin, Pons, Gérard, Garrido, María Jesús, Taminiau, Johannes, Benda, Norbert, Lentz, Frederike, Tshinanu, Flora Musuamba, Thomson, Andrew, Tomasi, Paolo, Ollivier, Cecile, Herold, Ralf, Manolis, Efthymios, Mahmood, Iftekhar, editor, and Burckart, Gilbert, editor
- Published
- 2016
- Full Text
- View/download PDF
18. The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline
- Author
-
Frost, Isabel, primary, Sati, Hatim, additional, Garcia-Vello, Pilar, additional, Hasso-Agopsowicz, Mateusz, additional, Lienhardt, Christian, additional, Gigante, Valeria, additional, and Beyer, Peter, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Reply to Kaye and Belley, “Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!”
- Author
-
Butler, Mark S., primary, Gigante, Valeria, additional, Sati, Hatim, additional, Paulin, Sarah, additional, Al-Sulaiman, Laila, additional, Rex, John H., additional, Fernandes, Prabhavathi, additional, Arias, Cesar A., additional, Paul, Mical, additional, Thwaites, Guy E., additional, Czaplewski, Lloyd, additional, Alm, Richard A., additional, Lienhardt, Christian, additional, Spigelman, Melvin, additional, Silver, Lynn L., additional, Ohmagari, Norio, additional, Kozlov, Roman, additional, Harbarth, Stephan, additional, and Beyer, Peter, additional
- Published
- 2022
- Full Text
- View/download PDF
20. WHO fungal priority pathogens list to guide research development and public health
- Author
-
Sati, Hatim, Beardsley, Justin, Alastruey-Izquierdo, Ana, Jan-Willem Alffenaar, Morrissey, Orla, Beyer, Peter, Gigante, Valeria, Garcia-Vello, Pilar, Arunaloke Chakrabart, Chiller, Tom, Colombo, Arnaldo, Nelesh Govender, Harrison, Tom, Oladele, Rita, Bongomin, Felix, Heim, Jutta, Perfect, John, Rickerts, Volker, Shin, Jong-Hee, Sorrell, Tania, Tacconelli, Evelina, Retno Wahyuningsih, Denning, David W., Tudela, Juan Luis Rodríguez, Nucci, Marcio, Other Contributors Are Named In The Report Aknowdegment, and Haileyesus Getahun
- Published
- 2022
- Full Text
- View/download PDF
21. Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed
- Author
-
Butler, Mark S., primary, Gigante, Valeria, additional, Sati, Hatim, additional, Paulin, Sarah, additional, Al-Sulaiman, Laila, additional, Rex, John H., additional, Fernandes, Prabhavathi, additional, Arias, Cesar A., additional, Paul, Mical, additional, Thwaites, Guy E., additional, Czaplewski, Lloyd, additional, Alm, Richard A., additional, Lienhardt, Christian, additional, Spigelman, Melvin, additional, Silver, Lynn L., additional, Ohmagari, Norio, additional, Kozlov, Roman, additional, Harbarth, Stephan, additional, and Beyer, Peter, additional
- Published
- 2022
- Full Text
- View/download PDF
22. Recent advances and challenges in antibacterial drug development
- Author
-
Gigante, Valeria, primary, Sati, Hatim, additional, and Beyer, Peter, additional
- Published
- 2022
- Full Text
- View/download PDF
23. Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system
- Author
-
Gigante, Valeria, primary, Pauletti, Giovanni M., additional, Kopp, Sabine, additional, Xu, Minghze, additional, Gonzalez-Alvarez, Isabel, additional, Merino, Virginia, additional, McIntosh, Michelle P., additional, Wessels, Anita, additional, Lee, Beom-Jin, additional, Rezende, Kênnia Rocha, additional, Scriba, Gerhard K.E., additional, Jadaun, Gaurav P. S., additional, and Bermejo, Marival, additional
- Published
- 2020
- Full Text
- View/download PDF
24. Synthesis of high payload nanohydrogels for the ecapsulation of hydrophilic molecules via inverse miniemulsion polymerization: caffeine as a case study
- Author
-
Artusio, Fiora, primary, Ferri, Ada, additional, Gigante, Valeria, additional, Massella, Daniele, additional, Mazzarino, Italo, additional, Sangermano, Marco, additional, Barresi, Antonello, additional, and Pisano, Roberto, additional
- Published
- 2019
- Full Text
- View/download PDF
25. Points to consider on the different approaches -- including HBEL -- to establish carryover limits in cleaning validation for identification of contamination risks when manufacturing in shared facilities.
- Author
-
Gigante, Valeria
- Subjects
- *
CLEANING compounds , *DOCUMENTATION , *DRUG adulteration , *DOSAGE forms of drugs , *PHARMACEUTICAL industry , *QUALITY assurance , *RISK assessment , *RISK management in business , *MANUFACTURING industries , *EQUIPMENT maintenance & repair - Abstract
The article discusses the points to consider on the different approaches including Health-Based Exposure Limits to establish carryover limits in cleaning validation for identification of contamination risks when manufacturing in shared facilities. Topics include discuss the different possible approaches – including methods that account for pharmacological and toxicological data; and clarification on cleaning validation and approaches to cleaning validation in multiproduct facilities.
- Published
- 2020
26. "MENS" E "ANIMUS" IN CATULLO FORMA POETICA ED ELABORAZIONE CONCETTUALE
- Author
-
Gigante, Valeria
- Published
- 1978
27. Commentary on the MID3 Good Practices Paper.
- Author
-
Manolis, Efthymios, Brogren, Jacob, Cole, Susan, Hay, Justin L., Nordmark, Anna, Karlsson, Kristin E., Lentz, Frederike, Benda, Norbert, Wangorsch, Gaby, Pons, Gerard, Zhao, Wei, Gigante, Valeria, Serone, Francesca, Standing, Joseph F., Dokoumetzidis, Aris, Vakkilainen, Juha, van den Heuvel, Michiel, Mangas Sanjuan, Victor, Taminiau, Johannes, and Kerwash, Essam
- Subjects
DRUG development ,MEDICAL practice ,SIMULATION methods & models - Abstract
During the last 10 years the European Medicines Agency (EMA) organized a number of workshops on modeling and simulation, working towards greater integration of modeling and simulation (M&S) in the development and regulatory assessment of medicines. In the 2011 EMA - European Federation of Pharmaceutical Industries and Associations (EFPIA) Workshop on Modelling and Simulation, European regulators agreed to the necessity to build expertise to be able to review M&S data provided by companies in their dossier. This led to the establishment of the EMA Modelling and Simulation Working Group (MSWG). Also, there was agreement reached on the need for harmonization on good M&S practices and for continuing dialog across all parties. The MSWG acknowledges the initiative of the EFPIA Model-Informed Drug Discovery and Development (MID3) group in promoting greater consistency in practice, application, and documentation of M&S and considers the paper is an important contribution towards achieving this objective. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.
- Author
-
Gigante V, Alm RA, Melchiorri D, Rocke T, Arias CA, Czaplewski L, Fernandes P, Franceschi F, Harbarth S, Kozlov R, Lienhardt C, Ohmagari N, Ogilvie LA, Paul M, Rex JH, Silver LL, Spigelman M, Sati H, and Cameron AM
- Subjects
- Humans, Drug Development, Global Health, Bacterial Infections drug therapy, Bacterial Infections microbiology, Drug Resistance, Bacterial, Animals, Drug Evaluation, Preclinical, World Health Organization, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use
- Abstract
Antimicrobial resistance (AMR) is a major global health threat estimated to have caused the deaths of 1.27 million people in 2019, which is more than HIV/AIDS and malaria deaths combined. AMR also has significant consequences on the global economy. If not properly addressed, AMR could immensely impact the world's economy, further increasing the poverty burden in low- and middle-income countries. To mitigate the risk of a post-antibiotic society, where the ability to effectively treat common bacterial infections is being severely threatened, it is necessary to establish a continuous supply of new and novel antibacterial medicines. However, there are gaps in the current pipeline that will prove difficult to address, given the time required to develop new agents. To understand the status of upstream antibiotic development and the challenges faced by drug developers in the early development stage, the World Health Organization has regularly assessed the preclinical and clinical antibacterial development pipeline. The review identifies potential new classes of antibiotics or novel mechanisms of action that can better address resistant bacterial strains. This proactive approach is necessary to stay ahead of evolving resistance patterns and to support the availability of effective treatment options. This review examines the trends in preclinical development and attempts to identify gaps and potential opportunities to overcome the numerous hurdles in the early stages of the antibacterial research and development space., Competing Interests: P.F., F.F., V.G., S.H., C.L., N.O., T.R., M.S., L.A.O., D.M., A.M.C., and H.S. declare no conflicts of interest. R.A.A. works for CARB-X. C.A.A. received support from MSD and Entasis in the last 4 years. R.K. provided consultation for MSD and Pfizer between 2016 and 2020. M.P. provided consultation for Shionogi in 2021 and had a grant from Pfizer in 2020. J.H.R. has been chief medical officer and director of F2G, Ltd.; editor-in-chief of AMR.Solutions; operating partner and consultant of Advent Life Sciences; has received grant support from Wellcome Trust; sits on the scientific advisory boards of Bugworks Research, Inc., Basilea Pharmaceutica, Forge Therapeutics, Inc., Novo Holdings, Roche Pharma Research & Early Development, Sumitovant, and the AMR Action Fund; and received consulting fees from Forge Therapeutics, Inc., Innocoll, Vedanta, Progenity, Nosopharm SA, Roivant Sciences, Shionogi Inc., GlaxoSmithKline, and Pfizer Pharmaceuticals. He is currently a shareholder in AstraZeneca Pharmaceuticals, F2G, Ltd, Advent Life Sciences, Zikani Therapeutics, and Bugworks Research, Inc. L.C. is a non-executive director at Curza and has received consulting fees from Clarametyx. He also sat on the Novo Repair Impact Fund SAB. L.L.S. provides consulting and/or scientific advisory board service for Blacksmith, Curza, Techulon, Linnaeus, Prokaryotics, NOVO-REPAIR, IMI-ENABLE, and AMED.
- Published
- 2024
- Full Text
- View/download PDF
29. Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens.
- Author
-
Marinelli T, Kim HY, Halliday CL, Garnham K, Bupha-Intr O, Dao A, Morris AJ, Alastruey-Izquierdo A, Colombo A, Rickerts V, Perfect J, Denning DW, Nucci M, Hamers RL, Cassini A, Oladele R, Sorrell TC, Ramon-Pardo P, Fusire T, Chiller TM, Wahyuningsih R, Forastiero A, Al-Nuseirat A, Beyer P, Gigante V, Beardsley J, Sati H, Alffenaar JW, and Morrissey CO
- Subjects
- Humans, World Health Organization, Mycoses epidemiology, Mycoses microbiology, Fusariosis microbiology, Fusariosis epidemiology, Ascomycota drug effects, Invasive Fungal Infections, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Fusarium drug effects, Fusarium isolation & purification, Scedosporium drug effects, Scedosporium isolation & purification, Scedosporium classification, Microbial Sensitivity Tests
- Abstract
Recognizing the growing global burden of fungal infections, the World Health Organization established a process to develop a priority list of fungal pathogens (FPPL). In this systematic review, we aimed to evaluate the epidemiology and impact of infections caused by Fusarium spp., Scedosporium spp., and Lomentospora prolificans to inform the first FPPL. PubMed and Web of Sciences databases were searched to identify studies published between January 1, 2011 and February 23, 2021, reporting on mortality, complications and sequelae, antifungal susceptibility, preventability, annual incidence, and trends. Overall, 20, 11, and 9 articles were included for Fusarium spp., Scedosporium spp., and L. prolificans, respectively. Mortality rates were high in those with invasive fusariosis, scedosporiosis, and lomentosporiosis (42.9%-66.7%, 42.4%-46.9%, and 50.0%-71.4%, respectively). Antifungal susceptibility data, based on small isolate numbers, showed high minimum inhibitory concentrations (MIC)/minimum effective concentrations for most currently available antifungal agents. The median/mode MIC for itraconazole and isavuconazole were ≥16 mg/l for all three pathogens. Based on limited data, these fungi are emerging. Invasive fusariosis increased from 0.08 cases/100 000 admissions to 0.22 cases/100 000 admissions over the time periods of 2000-2009 and 2010-2015, respectively, and in lung transplant recipients, Scedosporium spp. and L. prolificans were only detected from 2014 onwards. Global surveillance to better delineate antifungal susceptibility, risk factors, sequelae, and outcomes is required., (© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.